These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

605 related articles for article (PubMed ID: 23384167)

  • 21. Detecting interval metastases and response assessment using 18F-FDG PET/CT after neoadjuvant chemoradiotherapy for esophageal cancer.
    Stiekema J; Vermeulen D; Vegt E; Voncken FE; Aleman BM; Sanders J; Boot H; van Sandick JW
    Clin Nucl Med; 2014 Oct; 39(10):862-7. PubMed ID: 25140549
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of dual-time combined 18-fluorodeoxyglucose positron emission tomography and computed tomography in the staging and restaging workup of locally advanced rectal cancer, treated with preoperative chemoradiation therapy and radical surgery.
    Capirci C; Rubello D; Pasini F; Galeotti F; Bianchini E; Del Favero G; Panzavolta R; Crepaldi G; Rampin L; Facci E; Gava M; Banti E; Marano G
    Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1461-9. PubMed ID: 19419820
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prediction of neoadjuvant radiation chemotherapy response and survival using pretreatment [(18)F]FDG PET/CT scans in locally advanced rectal cancer.
    Bang JI; Ha S; Kang SB; Lee KW; Lee HS; Kim JS; Oh HK; Lee HY; Kim SE
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):422-31. PubMed ID: 26338180
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimal Interval for
    Kawai K; Nozawa H; Hata K; Tanaka T; Nishikawa T; Oba K; Watanabe T
    Clin Colorectal Cancer; 2018 Jun; 17(2):e163-e170. PubMed ID: 29208445
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adaptive Individualized high-dose preoperAtive (AIDA) chemoradiation in high-risk rectal cancer: a phase II trial.
    Guido A; Cuicchi D; Castellucci P; Cellini F; Di Fabio F; Llimpe FLR; Strigari L; Buwenge M; Cilla S; Deodato F; Macchia G; Galietta E; Golfieri R; Ardizzoni A; Zagari RM; Fanti S; Poggioli G; Fuccio L; Morganti AG
    Eur J Nucl Med Mol Imaging; 2023 Jan; 50(2):572-580. PubMed ID: 36127416
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of
    Rufini V; Collarino A; Calcagni ML; Meduri GM; Fuoco V; Pasciuto T; Testa AC; Ferrandina G; Gambacorta MA; Campitelli M; Gui B; Zannoni G; Manfredi R; Scambia G; Giordano A
    Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1228-1238. PubMed ID: 31414206
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Volumetric parameters of 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography/computed tomography can predict histopathologic treatment response after neoadjuvant chemoradiotherapy in pancreatic adenocarcinoma.
    Sakane M; Tatsumi M; Hori M; Onishi H; Tsuboyama T; Nakamoto A; Ota T; Eguchi H; Wakasa K; Hatazawa J; Tomiyama N
    Eur J Radiol; 2017 Sep; 94():64-69. PubMed ID: 28712692
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic Value of Total Lesion Glycolysis Measured by 18F-FDG-PET/CT in Patients with Colorectal Cancer.
    Ogawa S; Itabashi M; Kondo C; Momose M; Sakai S; Kameoka S
    Anticancer Res; 2015 Jun; 35(6):3495-500. PubMed ID: 26026116
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Textural Parameters of Tumor Heterogeneity in ¹⁸F-FDG PET/CT for Therapy Response Assessment and Prognosis in Patients with Locally Advanced Rectal Cancer.
    Bundschuh RA; Dinges J; Neumann L; Seyfried M; Zsótér N; Papp L; Rosenberg R; Becker K; Astner ST; Henninger M; Herrmann K; Ziegler SI; Schwaiger M; Essler M
    J Nucl Med; 2014 Jun; 55(6):891-7. PubMed ID: 24752672
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The predictive value of 18F-FDG PET/CT for assessing pathological response and survival in locally advanced rectal cancer after neoadjuvant radiochemotherapy.
    Leccisotti L; Gambacorta MA; de Waure C; Stefanelli A; Barbaro B; Vecchio FM; Coco C; Persiani R; Crucitti A; Tortorelli AP; Giordano A; Valentini V
    Eur J Nucl Med Mol Imaging; 2015 Apr; 42(5):657-66. PubMed ID: 25687534
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Spatial-temporal [¹⁸F]FDG-PET features for predicting pathologic response of esophageal cancer to neoadjuvant chemoradiation therapy.
    Tan S; Kligerman S; Chen W; Lu M; Kim G; Feigenberg S; D'Souza WD; Suntharalingam M; Lu W
    Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1375-82. PubMed ID: 23219566
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The value of liver-based standardized uptake value and other quantitative 18F-FDG PET-CT parameters in neoadjuvant therapy response in patients with locally advanced rectal cancer: correlation with histopathology.
    Koç M; Kaya GÇ; Demir Y; Sürücü E; Sarioğlu S; Obuz F; Öztop İ; Görken İB; Sökmen S
    Nucl Med Commun; 2015 Sep; 36(9):898-907. PubMed ID: 25969176
    [TBL] [Abstract][Full Text] [Related]  

  • 33. To determine the utility of fluorodeoxyglucose-positron emission tomography-computed tomography scan in predicting pathological response in operated carcinoma rectum patients after initial neoadjuvant chemoradiation.
    Sharma N; Takkar P; Purkayastha A; Singh BK
    J Cancer Res Ther; 2019; 15(1):9-14. PubMed ID: 30880747
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Accurate prediction of pathological rectal tumor response after two weeks of preoperative radiochemotherapy using (18)F-fluorodeoxyglucose-positron emission tomography-computed tomography imaging.
    Janssen MH; Ollers MC; Riedl RG; van den Bogaard J; Buijsen J; van Stiphout RG; Aerts HJ; Lambin P; Lammering G
    Int J Radiat Oncol Biol Phys; 2010 Jun; 77(2):392-9. PubMed ID: 19646825
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The efficiency of
    Uemura M; Ikeda M; Handa R; Danno K; Nishimura J; Hata T; Takemasa I; Mizushima T; Yamamoto H; Sekimoto M; Doki Y; Eguchi H
    BMC Cancer; 2021 Oct; 21(1):1132. PubMed ID: 34674666
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early repeated 18F-FDG PET scans during neoadjuvant chemoradiation fail to predict histopathologic response or survival benefit in adenocarcinoma of the esophagus.
    Malik V; Lucey JA; Duffy GJ; Wilson L; McNamara L; Keogan M; Gillham C; Reynolds JV
    J Nucl Med; 2010 Dec; 51(12):1863-9. PubMed ID: 21078796
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictive value of (18)FDG PET-CT for tumour response in patients with locally advanced rectal cancer treated by preoperative chemoradiotherapy.
    Kim JW; Kim HC; Park JW; Park SC; Sohn DK; Choi HS; Kim DY; Chang HJ; Baek JY; Kim SY; Kim SK; Oh JH
    Int J Colorectal Dis; 2013 Sep; 28(9):1217-24. PubMed ID: 23404344
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic utility of serial
    Fernando S; Lin M; Pham TT; Chong S; Ip E; Wong K; Chua W; Ng W; Lin P; Lim S
    Br J Radiol; 2020 Jan; 93(1105):20190455. PubMed ID: 31617737
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Response to neoadjuvant therapy in locally advanced rectal cancer: assessment with diffusion-weighted MR imaging and 18FDG PET/CT.
    Ippolito D; Monguzzi L; Guerra L; Deponti E; Gardani G; Messa C; Sironi S
    Abdom Imaging; 2012 Dec; 37(6):1032-40. PubMed ID: 22270580
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.